



## **5<sup>th</sup> GUILDFORD ADVANCED PAIN & SYMPTOM MANAGEMENT COURSES**

### **REFERENCE / READING LIST**

#### **WHO Cancer Pain Relief - 30yr of pain (control) - Dr Andrew Davies**

- Ahmedzai SH. Window of opportunity for pain control in the terminally ill. *Lancet* 2001; 357: 1304-05.
- Carlson CL. Effectiveness of the World Health Organization cancer pain relief guidelines. *Journal of Pain Research* 2016; 9: 525-34. [Full text available from course website].
- Jadad AR, Browman GP. The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation. *Journal of American Medical Association* 1995; 274: 1870-73.
- Leung L. From ladder to platform: a new concept for pain management. *Journal of Primary Healthcare* 2012; 4: 254-8.
- Raffa RB, Pergolizzi JV. A modern analgesics pain “pyramid”. *Journal of Clinical Pharmacy and Therapeutics* 2014; 39: 4-6.
- World Health Organization. *Cancer Pain Relief*. Geneva: WHO; 1986.
- World Health Organization. *Cancer Pain Relief*. 2nd ed. Geneva: WHO; 1996.

#### **NSAIDs - much of a muchness? - Dr Victor Pace**

- Bhala N, Emberson J, Merhi A et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. *Lancet* 2013; 382: 769-79.
- Kim J, Lee J, Shin CM et al. Risk of gastrointestinal bleeding and cardiovascular events due to NSAIDs in the diabetic elderly population. *BMJ Open Diabetes Research and Care* 2015; 3: e000133.
- Lanas A, Polo-Tomas M, Roncales P et al. Prescription of and adherence to non-steroidal anti-inflammatory drugs and gastroprotective agents in at-risk gastrointestinal patients. *American Journal of Gastroenterology* 2012; 107: 707-14.
- Lim YJ, Chun HJ. Recent advances in NSAIDs-induced enteropathy therapeutics: new options, new challenges. *Gastroenterology Research and Practice* 2013; 2013: 761060.
- Masso Gonzalez EL, Patrignani P, Tacconelli S et al. Variability among nonsteroidal anti-inflammatory drugs in risk of upper gastrointestinal bleeding. *Arthritis and Rheumatism* 2010; 62: 1592-601.
- McCormack K, Brune K. Dissociation between the antinociceptive and anti-inflammatory effects of the nonsteroidal anti-inflammatory drugs. A survey of their analgesic efficacy. *Drugs* 1991; 41: 533-47.

- McNicol E, Strassels SA, Goudas L et al. NSAIDs or paracetamol, alone or combined with opioids, for cancer pain. *Cochrane Database of Systematic Reviews* 2005: CD005180.
- Pai AB. Keeping kidneys safe: the pharmacist's role in NSAID avoidance in high-risk patients. *Journal of American Pharmacists Association* (2003) 2015; 55: e15-23.
- Rannou F, Pelletier JP, Martel-Pelletier J. Efficacy and safety of topical NSAIDs in the management of osteoarthritis: evidence from real-life setting trials and surveys. *Seminars in Arthritis and Rheumatism* 2016; 45(4 Suppl): S18-21.
- Shau WY, Chen HC, Chen ST et al. Risk of new acute myocardial infarction hospitalization associated with use of oral and parenteral non-steroidal anti-inflammation drugs (NSAIDs): a case-crossover study of Taiwan's National Health Insurance claims database and review of current evidence. *BMC Cardiovascular Disorders* 2012; 12: 4.
- Yiannakopoulou E. Pharmacogenomics of acetylsalicylic acid and other nonsteroidal anti-inflammatory agents: clinical implications. *European Journal of Clinical Pharmacology* 2013; 69: 1369-73.

### **Opioid receptors: an overview - Prof Graeme Henderson**

- Ferré S, Casadó V, Devi LA et al. G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives. *Pharmacol Rev* 2014; 66: 413-34.
- Kieffer BL. Drug discovery: designing the ideal opioid. *Nature* 2016 [Epub ahead of print].
- Law PY, Reggio PH, Loh HH. Opioid receptors: toward separation of analgesic from undesirable effects. *Trends Biochem Sci* 2013; 38: 275-82.
- Luttrell LM, Gesty-Palmer D. Beyond desensitization: physiological relevance of arrestin-dependent signaling. *Pharmacol Rev* 2010; 62: 305-30.
- Ohbuchi K, Miyagi C, Suzuki Y et al. Ignavine: a novel allosteric modulator of the  $\mu$  opioid receptor. *Sci Rep* 2016; 6: 31748.

### **Opioids - silent killers? - Dr Jason Boland**

- Boland J, Boland E, Brooks D. Importance of the correct diagnosis of opioid-induced respiratory depression in adult cancer patients and titration of naloxone. *Clin Med (Lond)* 2013; 13: 149-51.
- Boland JW, McWilliams K, Ahmedzai SH et al. Effects of opioids on immunological parameters that are relevant to anti-tumour immune potential in patients with cancer: a systematic literature review. *Br J Cancer* 2014; 111: 866-73.
- Boland JW, Ziegler L, Boland EG et al. Is regular systemic opioid analgesia associated with shorter survival in adult patients with cancer? A systematic literature review. *Pain* 2015; 156: 2152-63.
- Boland JW, Bennett MI. Opioids do not influence metastasis in experimental animal cancer models. *Pain* 2016; 157: 1173.
- Portenoy RK, Sibirceva U, Smout R et al. Opioid use and survival at the end of life: a survey of a hospice population. *J Pain Symptom Manage* 2006; 32: 532-40.
- Smith TJ, Staats PS, Deer T et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. *J Clin Oncol* 2002; 20: 4040-9.

- Zylla D, Gourley BL, Vang D et al. Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer. *Cancer* 2013; 119: 4103-10.

### **Opioid abuse / addiction in pain patients - Dr Kath Webber**

- Hojsted J, Sjogren P. Addiction to opioids in chronic pain patients: a literature review. *European Journal of Pain* 2007; 11: 490-518. [Full text available from course website].
- Hojsted J, Nieben PR, Guldstrand SK et al. Classification and identification of opioid addiction in chronic pain patients. *European Journal of Pain* 2010; 14: 1014-20.
- Kircher S, Zecry J, Apfelbaum SM et al. Understanding and treating opioid addiction in a patient with cancer pain. *Journal of Pain* 2011; 12: 1025-31.
- Modesto-Lowe V, Girard L, Chaplin M. Cancer pain in the opioid addicted patient: can we treat it right? *Journal of Opioid Management* 2012; 8: 167-76.

### **Pharmacogenetics and drug interactions - Dr Andrew Dickman**

- Hocum BT et al. Cytochrome P-450 gene and drug interaction analysis in patients referred for pharmacogenetic testing. *American Journal of Health System Pharmacy* 2016; 73: 61-7. [Full text available from course website].
- Kotlinska-Lemieszek A et al. Clinically significant drug-drug interactions involving opioid analgesics used for pain treatment in patients with cancer: a systematic review. *Drug Design, Development and Therapy* 2015; 9: 5255-667. [Full text available from course website].
- Preissner SC et al. Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy. *Plos One* 2013; 82; e82562. [Full text available from course website].

### **Non-adherence - Dr Susan Salt**

- Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence. London: NICE; 2009.  
Available from:  
<https://www.nice.org.uk/Guidance/CG76>
- Ose D et al. Let's talk about medication concordance in rating medication among multimorbid patients and their general practitioners. *Patient Preference and Adherence* 2012; 6: 839-45.
- Tait RC et al. Racial/ethnic disparities in the assessment and treatment of pain. *American Psychologist* 2014; 69: 131-41.
- Meichenbaum D, Turk DC. Facilitating treatment adherence: a practitioner's guidebook. New York: Plenum Press; 1987.
- Broekmans S et al. Pharmacologic pain treatment in a multidisciplinary pain center: do patients adhere to the prescription of the physician? *Clinical Journal of Pain* 2010; 26: 81-6.
- Zeppetella G. How do terminally ill patients at home take their medication? *Palliative Medicine* 1999; 13: 469-75.
- Nguyen LM et al. Frequency and predictors of patient deviation from prescribed opioids and barriers to opioid pain management in patients with advanced cancer. *Journal of Pain and Symptom Management* 2013; 45: 506-16.

### **What else is new (pain)? - Dr Andrew Dickman / Dr Andrew Davies**

- Majithia N, Smith TJ, Coyne PJ et al. Scrambler therapy for the management of chronic pain. *Support Care Cancer* 2016; 24: 2807-14. [Full text available from course website].
- Marineo G, Iorno V, Gandini C et al. Scrambler therapy may relieve chronic neuropathic pain more effectively than guideline-based drug management. *J Pain Symptom Manage* 2012; 43: 87-95.

### **Breakthrough cancer pain - consensus and disagreement - Dr Andrew Davies**

- Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. *European Journal of Pain* 2009; 13: 331-8.
- Davies A, Buchanan A, Zeppetella G, Porta-Sales J, Likar R, Weismayr W et al. Breakthrough cancer pain: an observational study of 1000 European oncology patients. *Journal of Pain and Symptom Management* 2013; 46: 619-28.
- Webber K, Davies AN, Cowie MR. Accuracy of a diagnostic algorithm to diagnose breakthrough cancer pain as compared with clinical assessment. *Journal of Pain and Symptom Management* 2015; 50: 495-500.

### **Cough / haemoptysis - Dr Clare Smith**

- Bolser DC. Central Mechanisms II: Pharmacology of Brainstem Pathways. *Handb Exp Pharmacol* 2009: 203-17.
- Clinical Knowledge Summaries: Palliative Care - Cough  
Available from:  
<http://cks.nice.org.uk/palliative-care-cough#!scenario>
- Kvale PA. Chronic cough due to lung tumors. ACCP evidence-based clinical practice guidelines. *Chest* 2006; 129 (1 Suppl): 147S-153S.
- Larici AR et al. Diagnosis and management of hemoptysis. *Diagn Interv Radiol* 2014; 20: 299-309.
- Molassiotis A et al. Pharmacological and non-pharmacological interventions for cough in adults with respiratory and non-respiratory diseases: a systematic review of the literature. *Respir Med* 2010; 104: 934-44.
- Molassiotis A et al. Clinical expert guidelines for the management of cough in lung cancer: report of a UK task group on cough. *Cough* 2010; 6: 9.
- Molassiotis A. Interventions for cough in cancer. *Cochrane Database Syst Rev* 2015; 5: CD007881.[Epub ahead print].
- Ryan NM et al. Gabapentin for refractory chronic cough: a randomised, double blind, placebo controlled trial. *Lancet* 2012; 380: 1583-9.
- Scottish Palliative Care guidelines: Cough  
Available from:  
<http://www.palliativecareguidelines.scot.nhs.uk/guidelines/symptom-control/Cough.aspx>
- Wee B et al. Management of chronic cough in patients receiving palliative care: review of evidence and recommendations by a task group of the Association for Palliative Medicine of Great Britain and Ireland. *Palliat Med*, 2012; 26: 780-7.
- Yancy WS et al. Efficacy and tolerability of treatments for chronic cough: a systematic review and meta-analysis. *Chest* 2013; 144: 1827-38.

## **Gastroparesis and upper GI problems - Dr Andrew Davies**

- Camilleri M, Parkman HP, Shafi MA et al. Clinical guideline: management of gastroparesis. *Am J Gastroenterol* 2013; 108: 18-38. [Full text available from course website].
- Franco M, Koulaeva E. Nasogastric tube insertion followed by intravenous and oral erythromycin in refractory nausea and vomiting secondary to paraneoplastic gastroparesis: a case report. *Palliat Med* 2014; 28: 986-9.
- McCarty TR, Rustagi T. Endoscopic treatment of gastroparesis. *World J Gastroenterol* 2015; 21: 6842-9.
- Moretto EN, Wee B, Wiffen PJ, Murchison AG. Interventions for treating persistent and intractable hiccups in adults. *Cochrane Database of Systematic Reviews* 2013, Issue 1. Art. No.: CD008768. [Full text available from course website].
- National Institute for Health and Care Excellence. Clinical Knowledge Summary - Hiccups.  
Available from:  
<http://cks.nice.org.uk/hiccups>
- Quigley EM. Prokinetics in the management of functional gastrointestinal disorders. *J Neurogastroenterol Motil* 2015; 21: 330-6.
- Steger M, Schneemann M, Fox M. Systematic review: the pathogenesis and pharmacological treatment of hiccups. *Aliment Pharmacol Ther* 2015; 42: 1037-50. [Full text available from course website].
- Twycross R, Wilcock A, Howard P. *Palliative Care Formulary* 5<sup>th</sup> edition. Nottingham: palliativedrugs.com; 2014.

## **Diarrhoea - Dr Nigel Sykes**

- Alam NH et al. Efficacy and tolerability of racecadotril in the treatment of cholera in adults: a double blind, randomised, controlled clinical trial. *Gut* 2003; 52: 1419-23.
- Angarone M et al. Diarrhea in solid organ transplant recipients. *Curr Opin Infect Dis* 2015; 28: 308-16.
- Asmuth DM et al. Oral serum-derived bovine immunoglobulin improves duodenal immune reconstitution and absorption function in patients with HIV enteropathy. *AIDS* 2013; 27: 2207-17.
- Benson AB et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. *J Clin Oncol*, 2004; 22: 2918-26.
- Binder HJ et al. Oral rehydration therapy in the second decade of the twenty-first century. *Curr Gastroenterol Rep* 2014; 16: 376.
- Braga Neto MB et al. Evaluation of HIV protease and nucleoside reverse transcriptase inhibitors on proliferation, necrosis, apoptosis in intestinal epithelial cells and electrolyte and water transport and epithelial barrier function in mice. *BMC Gastroenterol* 2010; 10: 90.
- Clay PG et al. Noninfectious diarrhea in HIV seropositive individuals: a review of prevalence rates, etiology, and management in the era of combination antiretroviral therapy. *Infect Dis Ther* 2014; 3: 103-22.
- Hamza H et al. Racecadotril versus placebo in the treatment of acute diarrhoea in adults. *Aliment Pharmacol Ther* 1999; 13(Suppl 6): 15-9.
- Hawley P et al. Implementation of the Victoria Bowel Performance Scale. *J Pain Symptom Manage* 2011; 42: 946-53.

- Helderman JH et al. Gastrointestinal complications of transplant immunosuppression. *J Am Soc Nephrol* 2002; 13: 277-87.
- Ko EA et al. Chloride channel inhibition by a red wine extract and a synthetic small molecule prevents rotaviral secretory diarrhoea in neonatal mice. *Gut* 2014; 63: 1120-9.
- Ma Q et al. Pharmacogenetics, pharmacogenomics and individualized medicine. *Pharmacol Rev* 2011; 63: 437-59.
- Manichanh C et al. The gut microbiota predispose to the pathophysiology of acute post-radiotherapy diarrhea. *Am J Gastroenterol* 2008;103: 1754-61.
- Mukwaya G et al. Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers. *Antimicrob Agents Chemother* 2005; 49: 4903-10.
- Nightingale J et al. Guidelines for management of patients with a short bowel. *Gut* 2006; 55(Suppl 4): iv1-12.
- Sykes N. Diarrhoea. In: Cherny N, Fallon M, Kaasa S, Portenoy R, Currow D (eds), *Oxford Textbook of Palliative Medicine*, 5th edition. Oxford: Oxford University Press; 2015. pp. 680-5.
- Thiagarajah JR et al. Secretory diarrhoea: mechanisms and emerging therapies. *Nat Rev Gastroenterol Hepatol* 2015; 12: 446-57.
- Tradtrantip L et al. Antidiarrheal efficacy and cellular mechanisms of a Thai herbal remedy. *PLoS Negl Trop Dis*, 2014; 8: e2674.
- Twycross RG, Lack SA. *Control of Alimentary Symptoms in Far Advanced Cancer*. London: Churchill Livingstone; 1986. pp. 208-229.
- Wallace BD et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. *Science*, 2010; 330: 831-5.
- Xu L et al. Lysophosphatidic acid increases SLC26A3 expression in inflamed intestine and reduces diarrheal severity in C57BL/6 mice with dextran-sodium-sulfate-induced colitis. *Chin Med J (Engl)* 2014; 127: 1737-43.
- Zaman S et al. Antisecretory factor effectively and safely stops childhood diarrhoea: a placebo-controlled, randomised study. *Acta Pædiatrica*, 2014; 103: 659-64.

### **Ascites - Dr Marinos Pericleous & Dr Claire Kelly**

- American Association for the Study of Liver Disease. Management of adult patients with ascites due to cirrhosis: Update 2012.  
Available from:  
[http://www.aasld.org/sites/default/files/guideline\\_documents/141020\\_Guideline\\_Ascites\\_4UFb\\_2015.pdf](http://www.aasld.org/sites/default/files/guideline_documents/141020_Guideline_Ascites_4UFb_2015.pdf)
- Akriviadis EA et al. Utility of an algorithm in differentiating spontaneous from secondary bacterial peritonitis. *Gastroenterology* 1990; 98: 127-33.
- Boyer TD et al. Effect of indomethacin and prostaglandin A1 on renal function and plasma renin activity in alcoholic liver disease. *Gastroenterology* 1979; 77: 215-22.
- Dykes PW et al. Albumin exchange between plasma and ascitic fluid. *Clin Sci* 1968; 34: 185-97.
- European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. *J Hepatol* 2010; 53: 397-417.
- Grabau CM et al. Performance standards for therapeutic abdominal paracentesis. *Hepatology* 2004; 40: 484-8.

- Llach J et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. *Gastroenterology* 1988; 94: 482-7.
- Llamas MA et al. Bacterial translocation to mesenteric lymph nodes increases in chronic portal hypertensive rats. *Dig Dis Sci* 2010; 55: 2244-54.
- Moore KP et al. Guidelines on the management of ascites in cirrhosis *Gut* 2006; 55(Suppl 6): vi1-12.
- Pache I et al. Severe haemorrhage following abdominal paracentesis for ascites in patients with liver disease, *Aliment Pharmacol Ther* 2005; 21: 525-9.
- Peltekian KM et al. Cardiovascular, renal and neurohumoral responses to single large-volume paracentesis in patients with cirrhosis and diuretic-resistant ascites. *Am J Gastroenterol* 1997; 92: 394-9.
- Runyon BA et al. Optimization of ascitic fluid culture technique. *Gastroenterology* 1988; 95: 1351-5.
- Runyon BA et al. Bedside inoculation of blood culture bottles is superior to delayed inoculation in the detection of spontaneous bacterial peritonitis. *J Clin Microbiol* 1990; 28: 2811-2.
- Runyon BA et al. Ascitic fluid pH and lactate: insensitive and nonspecific tests in detecting ascitic fluid infection. *Hepatology* 1991; 13: 929-35.
- Runyon BA et al. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. *Ann Intern Med* 1992; 117: 215-20.
- Runyon BA. Care of patients with ascites. *N Engl J Med* 1994; 330: 337-42.
- Runyon BA. Ascites and spontaneous bacterial peritonitis, In: Feldman M, Friedman LS, Brandt LJ, eds. *Sleisenger & Fordtran's Gastrointestinal and Liver Disease*, 9th edition. Philadelphia: Saunders Elsevier; 2010. pp. 1517-41.
- Serste T et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. *Hepatology* 2010; 52: 1017-22.
- Sort P et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. *N Engl J Med* 1999; 341: 403-9.
- Wu SS et al. Ascitic fluid carcinoembryonic antigen and alkaline phosphatase levels for the differentiation of primary from secondary bacterial peritonitis with intestinal perforation. *J Hepatol* 2001; 34: 215-21.
- Becker G et al. Malignant ascites: systematic review and guideline for treatment. *Eur J Cancer* 2006; 42: 589-97.
- Courtney A et al. Prospective evaluation of the PleurX catheter when used to treat recurrent ascites associated with malignancy. *J Vasc Interv Radiol* 2008; 19: 1723-31.
- Heiss MM et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. *Int J Cancer* 2010; 127: 2209-21.
- Hirte HW et al. A randomized trial of paracentesis plus intraperitoneal tumor necrosis factor-alpha versus paracentesis alone in patients with symptomatic ascites from recurrent ovarian carcinoma. *Gynecol Oncol* 1997; 64: 80-7.
- NICE. The PleurX peritoneal catheter drainage system for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites. London: NICE; 2012.
- Pockros PJ et al. Mobilization of malignant ascites with diuretics is dependent on ascitic fluid characteristics. *Gastroenterology* 1992; 103: 1302-6.
- R  th U et al. Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites. *Eur J Cancer* 1991; 27: 121-5.

- Richard HM 3<sup>rd</sup> et al. Pleurx tunneled catheter in the management of malignant ascites. J Vasc Interv Radiol. 2001; 12: 373-5.
- Rosenberg S et al. Comparison of percutaneous management techniques for recurrent malignant ascites. J Vasc Interv Radiol 2004; 15: 1129-31.
- Saiz-Mendiguren R et al. Permanent tunneled drainage for malignant ascites: initial experience with the PleurX catheter. Radiologia 2010;. 52: 541-5.
- Seimetz D et al. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM × anti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev 2010; 36: 458-67.
- Stephenson J et al. The development of clinical guidelines on paracentesis for ascites related to malignancy. Palliat Med 2002; 16: 213-8.
- Tapping CR et al. PleurX drain use in the management of malignant ascites: safety, complications, long-term patency and factors predictive of success. Br J Radiol 2012; 85: 623-8.

### **What else is new (other symptoms)? - Dr Andrew Dickman / Dr Andrew Davies**

- Walsh D, Davis M, Ripamonti C et al. 2016 updated MASCC/ESMO consensus recommendations: management of nausea and vomiting in advanced cancer. Support Care Cancer 2016 Epub (ahead print).
- YouTube clip burning petroleum jelly  
<https://www.youtube.com/watch?v=8hAUKTnHlcg>
- YouTube clip burning oxygen tubing  
<https://www.youtube.com/watch?v=asumR-n2e6k>

### **Care for the dying 2020: key challenges for policy and practice - Prof John Ellershaw**

- Ellershaw JE, Lakhani M. Best care for the dying patient. BMJ 2013; 347: f4428.
- Knights D. In defence of the “tick-box approach”: why end of life care is no exception. Br J Gen Pract 2016; 66: 290-1. [Full text available from course website].
- Neuberger J. The LCP - what went right and what went wrong. British Journal of Hospital Medicine 2016; 77: 172-4. [Full text available from course website].